Physician profile
Tiffany Marum
NPI 1548466204
$4,093.20
in general payments reported to CMS, 2019-2025
29 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $195 · 2021: $652 · 2022: $477 · 2023: $1,128 · 2024: $652 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.16 | 2021-2025 | |
| Novo Nordisk INC | $557.33 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $482.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Indivior INC. | $420.69 | 2019-2025 | Sublocade |
| Pfizer INC. | $366.18 | 2020-2025 | |
| Merz North America, INC. | $164.09 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.90 | 2019-2022 | |
| Alkermes, INC. | $144.35 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $143.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $139.53 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Aimmune Therapeutics, INC. | $108.71 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.89 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $78.26 | 2020-2022 | |
| Braeburn INC. | $67.63 | 2025 | Brixadi |
| Astellas Pharma US INC | $66.03 | 2023 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.55 | 2019-2024 | Gardasil, Vaxelis, Capvaxive |
| Viiv Healthcare Company | $46.80 | 2025 | Apretude |
| Orexo US, INC. | $36.09 | 2022-2023 | Zubsolv |
| Allergan, INC. | $30.01 | 2020 | |
| Idorsia Pharmaceuticals US INC | $28.21 | 2023 | Quviviq |
| Exact Sciences Corporation | $27.52 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $26.24 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.11 | 2023 | Nuedexta |
| Harmony Biosciences LLC | $24.06 | 2023 | Wakix |
| Avanir Pharmaceuticals, INC. | $23.77 | 2022 | |
| Adlon Therapeutics L.P. | $20.91 | 2020 | |
| Dexcom, INC. | $16.89 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $16.26 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $16.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Marum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.